Specifically, findings support the effectiveness of Tecfidera (dimethyl fumarate) and Tysabri (natalizumab) used early in the disease’s course, as well as the safety of Avonex (interferon-beta 1a), and Plegridy (peginterferon beta-1a) in pregnancy.
Biogen will also present data showing the potential utility of serum neurofilament light (sNfL) as a biomarker of MS disease activity and as a tool for monitoring treatment. Updates on ways to improve assessing changes in cognition and other crucial MS outcomes through Biogen-sponsored MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions) will also be shared.
The company will hold more than 70 oral and poster presentations on its MS medications and research efforts to improve patient care at the 34th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), taking place Oct. 10-12 in Berlin.
“Biogen believes the need for finding new approaches to treat MS is as important as ever,” Michael Ehlers, MD, PhD, Biogen’s executive vice president of research and development, said in a press release. Ehlers added that the research being presented at ECTRIMS reflects the company’s “proven track record of developing innovative medicines for MS,” as well as its pursuit of “new clinical approaches aimed at generating data that will encourage more individualized treatment decisions to help meet the needs of people living with MS today and into the future.”
Among four presentations on Tecfidera, results from the long-running Phase 3 ENDORSE trial (NCT00835770) showed that treatment of newly diagnosed relapsing-remitting MS patients was associated with low annualized relapse rates — the number of confirmed relapses per year. Most patients remained free of confirmed disability progression, including some treated for up to nine years.
This will be the subject of “P920 – Delayed-release Dimethyl Fumarate Demonstrates Sustained Efficacy over Nine Years in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis,” to be presented on Thursday afternoon.
The ongoing five-year, real-world ESTEEM study (NCT02047097) showed similar benefits in RRMS patients treated with Tecfidera early in their disease course. The presentation “P595 – Real-world efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: interim results from ESTEEM” will cover these results on Wednesday. ESTEEM, an observational study of people in clinical care, is still enrolling patients; details are available here.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?